

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/tcr-21-1953	
Item	Question	Authors' Response (place “–” if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	–
3	What data in particular will be shared?	A five–genes risk model based on m6A related immune genes was developed (PKHD1, IGF2BP3, RORA, FRK and MZF1).
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique or survival data may be updated over time.

7	To whom will you share the data?	Kidney cancer researchers.
8	For what type of analysis or purpose?	To evaluate the significance of N6-methyladenosine methylation related immune biomarkers correlates with characteristics and prognosis in ccRCC.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: 8605849@163.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.